Document is current
Any future updates will be listed below
-
Authors
Igarashi, Ataru
Nishigaki, Nobuhiro
Kawakita, Yasushi
Tsujii, Noa
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 3 March 2026
First Online: 28 March 2026
Declarations
:
: The study protocol was approved by the Non-Profit Organization MINS Institutional Review Board (ID: 230222) and registered at the University hospital Medical Information Network Center (UMIN000051654) on July 20, 2023. Participants in the web-based surveys provided informed consent before starting the survey. As data from the JMDC claims database were retrospective and anonymous, informed consent was not required.
: Not applicable.
: AI reports that his affiliation, the Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, is an endowment department and is supported with an unrestricted grant from Takeda Pharmaceutical Company Limited.NN is a former employee of Takeda Pharmaceutical Company Limited. YK is an employee of Takeda Pharmaceutical Company Limited. NT belongs to an endowed chair founded by the Toyama prefecture in Japan and reports receiving personal fees from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, Yoshitomi Pharmaceutical Industries Ltd., and Nobelpharma Co., Ltd.
